MedTrace Logo

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

NCT02221141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-08-20

No results posted yet for this study

Summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Conditions

  • Left Ventricular Hypertrophy

Sponsors & Collaborators

  • Laurence Gabriel

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221141 on ClinicalTrials.gov